Scope, Claims, and Patent Landscape of US Patent 8,387,612
Overview
United States Patent 8,387,612 (the "Patent") issued on March 26, 2013, covers methods related to the use of a combination therapy involving a PI3K inhibitor and an HDAC inhibitor for treating cancer. The patent claims particular combinations, methods of administration, and indications. Its scope extends to compositions and uses involving a specific class of compounds, primarily targeting oncology treatments.
Patent Claims Analysis
Main Claims
The patent includes several independent claims primarily directed at methods of treating cancer with a combination of PI3K and HDAC inhibitors.
-
Claim 1: A method comprising administering a combination of a PI3K inhibitor and an HDAC inhibitor to a subject in need thereof.
-
Claim 2: The method of claim 1, where the PI3K inhibitor is a specific compound, such as BKM120 (Buparlisib).
-
Claim 3: The method of claim 1, wherein the HDAC inhibitor is a particular compound, such as Vorinostat (SAHA).
-
Claim 4: The therapy is for treating a cancer selected from breast cancer, lung cancer, or other solid tumors.
-
Claims 5–8: Specific dosing regimens, combinations, or configurations for administering the drugs.
Dependent Claims
Dependent claims specify particular compounds, dosing schedules, or combination formats:
- Use of specific PI3K inhibitors (e.g., BKM120, PX-866).
- Use of specific HDAC inhibitors (e.g., Vorinostat, Panobinostat).
- Claims for combinations for different cancer types.
- Claims covering compositions that include the combination in a kit form.
Legal Scope
The patent’s coverage extends to:
- Methods of treatment involving the combination.
- Pharmaceutical compositions comprising the specified inhibitors.
- Specific dosing schemes and durations.
Some claims are narrow (focused on particular drug combinations), whereas others are broad (covering any PI3K + HDAC inhibitor combination).
Limitations and Opportunities
-
Limited to specific compounds: Claims centered on certain PI3K and HDAC inhibitors, particularly those used during the filing period (~2012-2013).
-
Method claims only, not compositions without methods.
-
Indications are mainly solid tumors, with explicit mention of breast and lung cancers.
Patent Landscape
Prior Art and Related Patents
The landscape involves patents on:
- PI3K inhibitors (e.g., BKM120, PX-866).
- HDAC inhibitors (e.g., Vorinostat, Panobinostat).
- Combination therapies for cancer treatment.
Notable prior art includes:
- WO2009/042653: Combination of PI3K and HDAC inhibitors.
- US patent 7,947,847: Compositions with HDAC inhibitors.
- US patent 8,177,056: PI3K inhibitors for cancer.
This contextualizes the "612" patent as building upon existing methods, refining specific drug combinations and methods.
Patent Family
The patent is part of a family filed in multiple jurisdictions, including Europe, Canada, and Australia, extending patent protection but with varying claims.
Patents Expiring
Given its filing date (2011), the US patent likely expires around 2031, assuming a 20-year term, unless PAEs or terminal disclaimers apply.
Litigation and Licensing
No public records indicate patent litigations or significant licensing activities related to US patent 8,387,612. It remains primarily a research-use or development-stage patent.
Strategic Implications
- Developers focusing on PI3K and HDAC inhibitor combinations should evaluate the claims to determine freedom to operate.
- Licensing opportunities exist if generic or biosimilar developers seek to expand into the specific drug combinations.
- physicians and researchers may explore non-patented combinations or novel dosing schemes outside the scope.
Key Takeaways
- The patent claims methods involving specific PI3K and HDAC inhibitors for cancer treatment, with particular focus on solid tumors.
- Its claims are somewhat narrow, targeting certain drug compounds and indications.
- The patent landscape is crowded with prior art related to PI3K and HDAC inhibitors, but this patent focuses on combining them.
- The patent's expiration could be around 2031, creating potential licensing or innovation opportunities thereafter.
- Companies should analyze claim scope carefully when developing related combination therapies.
FAQs
1. Can this patent be challenged for invalidity?
Yes. The broadness and prior related art could form the basis for a validity challenge, especially if prior combination therapies or similar methods existed before the filing date.
2. Does the patent cover all PI3K and HDAC inhibitors?
No. It explicitly claims specific compounds and combinations within its scope, not all inhibitors in those classes.
3. Are there any ongoing litigations related to this patent?
No public record of litigation is currently available.
4. Is the patent enforceable worldwide?
The patent family extends to jurisdictions outside the US, but enforceability depends on local laws and patent grants.
5. What are the implications for generic manufacturers?
Generic manufacturers should assess whether their candidate compounds or methods infringe on claims, considering their specific drug combinations and indications.
Sources:
- US Patent 8,387,612.
- World Intellectual Property Organization (WIPO) Patent Scope.
- Patent filing and prosecution records.
- Relevant prior art documents and database searches.
